Published in Law and Health Weekly, March 18th, 2006
The patent grants EntreMed composition-of-matter intellectual property protection through 2020 for analogs of 2ME2 in oncology and a broad range of nononcology indications, including inflammatory and immune disorders, rheumatoid arthritis, and other diseases characterized by abnormal cell division (mitosis).
Panzem is a novel anticancer agent, which is part of a next generation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.